Alleima (ALLEI) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
1 Jun, 2026Market position and business overview
Leading provider of advanced stainless steels, special alloys, ultrafine medical wires, and industrial heating products with strong positions in niche markets.
Operates a fully integrated value chain with industry-leading R&D and global presence in 80 markets, 5 R&D centers, and 25+ production sites.
Premium offering across three divisions: Tube, Kanthal, and Strip, each holding top market positions in their respective segments.
Diverse customer base across oil & gas, industrial, medical, transportation, chemical, heating, consumer, mining, nuclear, and renewable energy sectors.
Financial performance and segment results
Revenues for R12 Q1'26 reached SEK 18,056 million with an adjusted EBIT of SEK 1,401 million and a margin of 7.8%.
Q1 2026 revenues were SEK 4,576 million, with organic revenue growth at -5% and adjusted EBIT margin at 8.4%.
Tube division saw organic order intake growth of -19% and revenue growth of -9%, with an adjusted EBIT margin of 8.9%.
Kanthal division achieved organic order intake growth of 14% and revenue growth of 8%, with an adjusted EBIT margin of 17.0%.
Strip division reported organic order intake growth of -16% and revenue growth of 5%, with an adjusted EBIT margin of 5.9%.
Strategic priorities and growth outlook
Focus on defending and growing market positions, improving margins, and operational excellence to drive returns on capital.
Targeted growth in medical, nuclear, industrial heating, chemical, and renewable energy segments, aiming for a higher share of revenues from these areas by 2030.
Value growth is projected to outpace capacity, with ambitions for improved margins through profitable segment mix and efficiency.
Latest events from Alleima
- FY 2025 revenues reached SEK 18,630 million with an 8.3% EBIT margin amid market uncertainty.ALLEI
Company presentation1 Jun 2026 - Order intake and revenues declined amid uncertainty, but key segments and balance sheet remained resilient.ALLEI
Q1 202627 Apr 2026 - Flat organic growth, strong cash flow, and improved EBIT amid robust market sentiment.ALLEI
Q2 20243 Feb 2026 - Flat 2025 revenue, strong cash flow, and SEK 2.50 dividend amid FX and market headwinds.ALLEI
Q4 20252 Feb 2026 - Organic revenue up 3%, EBIT margin 7%, with strong nuclear and medical investments.ALLEI
Q3 202419 Jan 2026 - Stable earnings, strong cash, and growth in key segments despite mixed market demand.ALLEI
Q4 20249 Jan 2026 - Strong Q1 growth and margins, but Q2 faces currency and metal price headwinds.ALLEI
Q1 202528 Dec 2025 - Profitability held up despite revenue declines and market uncertainty, with resilient margins.ALLEI
Q2 202516 Nov 2025 - Profitable growth, innovation, and sustainability drive expansion in high-value segments.ALLEI
CMD 20258 Nov 2025